Jiangsu Nhwa Pharmaceutical Co Ltd Total Liabilities
Jiangsu Nhwa Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has total liabilities worth CN¥1.17 Billion CNY (≈ $171.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Jiangsu Nhwa Pharmaceutical Co Ltd (002262) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
Total liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Jiangsu Nhwa Pharmaceutical Co Ltd (002262) investment intensity to see how much of total assets are deployed in long-term investments.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liechtensteinische Landesbank AG
SW:LLBN
|
Switzerland | CHF25.96 Billion |
|
Avient Corp
NYSE:AVNT
|
USA | $3.53 Billion |
|
Veracyte Inc
NASDAQ:VCYT
|
USA | $97.96 Million |
|
Star Health and Allied Insurance Company Limited
NSE:STARHEALTH
|
India | Rs165.13 Billion |
|
Lepu Medical Tech Beijing
SHE:300003
|
China | CN¥7.61 Billion |
|
Hafnia Limited
NYSE:HAFN
|
USA | $1.24 Billion |
|
Jiangsu Changshu Rural Commercial Bank Co Ltd
SHG:601128
|
China | CN¥384.66 Billion |
|
Hiwin Technologies Corp
TW:2049
|
Taiwan | NT$17.79 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Jiangsu Nhwa Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Jiangsu Nhwa Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Jiangsu Nhwa Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Nhwa Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.20 Billion ≈ $174.92 Million |
+2.47% |
| 2024-12-31 | CN¥1.17 Billion ≈ $170.69 Million |
+27.06% |
| 2023-12-31 | CN¥918.09 Million ≈ $134.35 Million |
+2.30% |
| 2022-12-31 | CN¥897.43 Million ≈ $131.32 Million |
+13.10% |
| 2021-12-31 | CN¥793.45 Million ≈ $116.11 Million |
+12.28% |
| 2020-12-31 | CN¥706.67 Million ≈ $103.41 Million |
+18.43% |
| 2019-12-31 | CN¥596.68 Million ≈ $87.31 Million |
-44.48% |
| 2018-12-31 | CN¥1.07 Billion ≈ $157.26 Million |
+27.90% |
| 2017-12-31 | CN¥840.24 Million ≈ $122.95 Million |
-1.26% |
| 2016-12-31 | CN¥850.97 Million ≈ $124.52 Million |
+17.60% |
| 2015-12-31 | CN¥723.60 Million ≈ $105.89 Million |
-16.21% |
| 2014-12-31 | CN¥863.61 Million ≈ $126.37 Million |
+18.28% |
| 2013-12-31 | CN¥730.13 Million ≈ $106.84 Million |
+10.22% |
| 2012-12-31 | CN¥662.41 Million ≈ $96.93 Million |
+23.22% |
| 2011-12-31 | CN¥537.59 Million ≈ $78.67 Million |
+9.32% |
| 2010-12-31 | CN¥491.74 Million ≈ $71.96 Million |
+27.83% |
| 2009-12-31 | CN¥384.68 Million ≈ $56.29 Million |
-0.25% |
| 2008-12-31 | CN¥385.66 Million ≈ $56.43 Million |
-13.22% |
| 2007-12-31 | CN¥444.39 Million ≈ $65.03 Million |
+16.44% |
| 2006-12-31 | CN¥381.63 Million ≈ $55.85 Million |
+6.86% |
| 2005-12-31 | CN¥357.12 Million ≈ $52.26 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more